A highly efficient method for the production and purification of recombinant human CXCL8

Sophie McKenna1, Sean Patrick Giblin2, Rosemarie Anne Bunn2*, Yingqi Xu1, Stephen John Matthews1, James Edward Pease2*

1 Department of Life Sciences, Imperial College London, London, United Kingdom, 2 National Heart and Lung Institute, Imperial College London, London, United Kingdom

* Current address: School of Medicine, University of Dundee, Dundee, United Kingdom

* j.pease@imperial.ac.uk

Abstract

Chemokines play diverse and fundamental roles in the immune system and human disease, which has prompted their structural and functional characterisation. Production of recombinant chemokines that are folded and bioactive is vital to their study but is limited by the stringent requirements of a native N-terminus for receptor activation and correct disulphide bonding required to stabilise the chemokine fold. Even when expressed as fusion proteins, overexpression of chemokines in E. coli tends to result in the formation of inclusion bodies, generating the additional steps of solubilisation and refolding. Here we present a novel method for producing soluble chemokines in relatively large amounts via a simple two-step purification procedure with no requirements for refolding. CXCL8 produced by this method has the correct chemokine fold as determined by NMR spectroscopy and in chemotaxis assays was indistinguishable from commercially available chemokines. We believe that this protocol significantly streamlines the generation of recombinant chemokines.

Introduction

Chemokines are key players in the recruitment and retention of leukocytes at tissue locations and function by activating specific G protein-coupled receptors (GPCRs) [1]. Over the last 30 years, chemokines have been the focus of much global research, since together with their receptors, they have been implicated in the pathogenesis of several clinically important diseases, ranging from atherosclerosis to HIV-infection [2]. Recombinant chemokine production has been key to these efforts but is not without challenges. Methods that focus on chemical synthesis or expression in E. coli typically yield unfolded, reduced, and inactive chemokines, necessitating refolding steps that can be time consuming and challenging to optimise. Generation of the native N-terminus of a chemokine, essential for activity, is a stringent requirement since truncation or extension can severely affect receptor activation. In mammalian hosts, a signal peptide of around 20 amino acids is typically cleaved to liberate the mature chemokine with full agonist activity. This process has to be mimicked in prokaryotic expression systems.
Pioneering studies by the groups of Ian Clark-Lewis and colleagues championed the use of solid-phase peptide sequencing. In particular, studies of the CXC chemokine CXCL8 (formerly known as interleukin-8) highlighted a requirement for the chemokine N-terminus for full agonist activity [3–5]. Expression of chemokines incorporating an N-terminal 6-Histidine tag such as those expressed in the pET23a vector [6] allows for simple purification by IMAC but the N-terminal extension generally leads to a loss of bio-activity. A classic example of this is the molecule Met-RANTES, a recombinant form of the chemokine CCL5 produced by Amanda Proudfoot and colleagues, which by virtue of the retained N-terminal methionine residue was serendipitously found to be a potent antagonist of multiple chemokine receptors, including the HIV-1 receptor CCR5 [7, 8]. Thioredoxin fusion has been utilised to promote disulphide bonding and generate the native chemokine N-terminus through Factor Xa mediated cleavage [9–12]. However, application of the thioredoxin fusion more widely is limited by the promiscuity of Factor Xa, which is prone to cutting at cryptic secondary sites in the protein of interest [13].

Recent advances, such as those published by the groups of Brian Volkman and Tracey Han-del, have utilised E. coli expression systems in which an N-terminal SUMO partner is fused to the mature chemokine sequence [14, 15]. The SUMO partner can be readily and specifically cleaved by ubiquitin like protease-1 (ULP1), if an SMT3 cleavage site is incorporated upstream of the native N-terminal sequence. However, despite this advance, overexpression of SUMO-chemokine fusion proteins typically results in their appearance as insoluble aggregates within E. coli inclusion bodies, requiring a subsequent refolding step that can be inefficient and lead to reduced yields.

Interleukin-8 (IL-8 or CXCL8) is a member of the ELR+ CXC chemokine family and has been studied extensively, [16–19]. CXCL8 acts as a major recruitment factor for neutrophils expressing the chemokine receptors CXCR1 and CXCR2 on their surface [20]. Interestingly, CXCL8 has been reported to undergo post-translational modification, notably N-terminal truncation by endogenous peptidases, which can markedly affect the potency and efficacy at both CXCR1 and CXCR2 reviewed by Vanheule and colleagues [21]. The 72 amino acid variant of CXCL8, CXCL8 (6–77), has been most extensively studied and is the predominant form isolated by activated PBMCs [22].

CXCL8 exists dynamically as a monomer or homodimer at low and high concentrations, respectively, with distinct recruitment profiles observed [23]. The high-resolution structure of CXCL8 has been determined by solution NMR and X-ray crystallography with the concentrations required for these studies associated with CXCL8 dimerization [24, 25]. The structure of the monomer subunit within the dimer encompasses an N-terminal loop followed by three antiparallel β-strands, and a C-terminal α-helix. Mutations that trap the monomeric or dimeric state have been structurally characterised and are consistent with the earlier studies, showing that the monomeric form differs with some disorder observed in the C-terminal helix [26].

Here we describe an optimised protocol for the purification of chemokines, using CXCL8 (6–77) as an exemplar, without additional refolding requirements. A recombinant SUMO-CXCL8 fusion protein was purified to homogeneity from the soluble lysate of E. coli Shuffle T7 Express cells via IMAC (immobilized metal affinity chromatography). Cleavage of the SUMO tag was efficient, and a second IMAC step resulted in the purification of CXCL8 with a native N-terminus. The chemokine produced by this protocol was shown to be correctly folded by NMR spectroscopy with bio-activity indistinguishable from that of commercially available CXCL8 as demonstrated by chemotaxis assays. This method could be applicable to wider chemokine production efforts, with the rapidity of this protocol (expression and
purification of the construct takes 5 days) a distinct advantage over traditional recombinant refolding approaches.

**Materials and methods**

**Materials**

All materials were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. Recombinant CXCL8 (6–77) and a human IL-8/CXCL8 DuoSet ELISA kit were purchased from BioTechne (Abingdon, UK). The pCI-CXCR1 construct was a kind gift of GlaxoSmithKline (Stevenage, UK). Oligonucleotide production and Sanger sequencing services were provided by MWG-Biotech (Ebersberg, Germany).

**Expression and purification of ULP1**

*Saccharomyces cerevisiae* Ubiquitin-like-specific protease 1 (ULP1) was expressed in pET-28a, a gift from Dr Zhihao Wang and Dr Bing Liu. The construct covers residues 403 to 621 and is in-frame with the N-terminal His-tag and thrombin cleavage site in the vector. ULP1 was expressed in BL21(DE3) cells grown at 37˚C until an optical density at 600 nm of 0.6 to 0.8, induced with 1 mM IPTG for 4 hours, and harvested by centrifugation (5000 x g for 15 minutes). Pellets were resuspended in 20 mM Tris.HCl pH 8.0, 350 mM NaCl, 20 mM imidazole, 5% glycerol, 1 mM β-mercaptoethanol and sonicated. Cell lysate was clarified at 38000 x g for 45 minutes and loaded on a 5ml HisTrap FF crude column (GE Healthcare) pre-equilibrated with lysis buffer. The column was washed with 10 column volumes of lysis buffer and ULP1 was eluted in lysis buffer with 300 mM imidazole. The eluate was applied to an S75 16/600 (GE Healthcare) size exclusion column equilibrated with 20 mM Tris.HCl, 150 mM NaCl, 1 mM Dithiothreitol (DTT) for further purification.

**Generation, expression and purification of CXCL8**

The pUC19 CXCL8 construct was a gift from Dr Joost Openheim (Addgene plasmid #17610), [27]. The cDNA sequence encoding the mature 72 amino acid chemokine (6–77) was amplified by the primers SUMO3-CXCL8 Forward: 5’-CAG CAG CAG ACG GGA GGT AGT GCT AAA GAA CTT AGA TGT CAG-3’ and SUMO3-CXCL8 Reverse: 5’-CTC GAA TTC GGA TCC TCA TGA ATT CTC AGC CCT CTT CAA AAA-3’ using CloneAmp™ HiFi Premix (Takara Bio Europe SAS, Saint-Germain-en-Laye, France) according to the manufacturer’s instructions. Using the same premix, the pSUMO-3 vector (Lifesensors Inc, Malvern, USA) was linearized using the primers SUMO3 Forward: 5’-TGA GGA TCC GAA TTC GAG CTC-3’ and SUMO3 Reverse 5’-ACC TCC GTG CTG CTG CTG G-3’. PCR products underwent DpnI fast digestion (ThermoFisher Scientific, Paisley, UK) prior to ligation using the In-Fusion HD system (Takara). The authenticity of the pSUMO-3-CXCL8 open reading frame was verified by Sanger sequencing on both strands of the plasmid (MWG Eurofins, Ebersberg Germany).

The pSUMO3-CXCL8 plasmid was subsequently introduced into chemically competent Shuffle T7 Express E coli (New England Biolabs, Hitchin, UK) and following selection, colonies were grown in LB media or minimal medium containing 15NH4Cl as the sole nitrogen source, both supplemented with carbenicillin. Cells were grown at 30˚C until an optical density at 600 nm of 0.6 to 0.8 was reached, then protein production induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG), grown for 4 hours at 30˚C, and finally harvested by centrifugation at 5000 x g for 15 minutes.
Bacterial pellets were resuspended in buffer A (20 mM Na phosphate pH 6.7, 500 mM NaCl, 20 mM imidazole) supplemented with a Complete™ Mini, EDTA-free Protease Inhibitor tablet (Roche, Welyn Garden City, UK) and sonicated. Cell lysates were clarified by centrifugation at 38000 x g for 45 minutes and loaded onto a 5ml HisTrap FF crude column (Cytiva, Amersham, UK) pre-equilibrated with buffer A. The column was washed with 5 column volumes of buffer A followed by a gradient over 20 column volumes to 100% buffer B (20 mM Na phosphate pH 6.7, 500 mM NaCl, 500 mM imidazole). The eluate was dialysed into 20 mM Na phosphate pH 6.7, 150 mM NaCl, 10% glycerol overnight at 4°C overnight. ULP1 was dialysed into the digestion buffer concurrently but separately. SUMO-3 removal was performed by incubating ULP1:SUMO3-CXCL8 at a ratio of 1:25 at 4°C for 48 hours with agitation. Separation of cleaved CXCL8 from the SUMO-3 tag and ULP-1 was achieved by loading the digested sample onto a 5ml HisTrap FF crude pre-equilibrated with buffer A and eluting with buffer A. ULP1, undigested SUMO3-CXCL8 and SUMO3 tag were subsequently eluted from the column with buffer B.

NMR spectroscopy

1D 1H spectra were recorded on 100 μM CXCL8 in 20 mM Na phosphate pH 6.7, 150 mM NaCl at 298 K. Spectral assignment of [U-15N]-labelled CXCL8 was performed at 500 μM in 20 mM Na phosphate pH 6.5, 100 mM NaCl, 10% D2O acquired at 298 K. 15N-HSQC, 15N-HSQC-TOCSY and 15N-HSQC-NOESY spectra were recorded and used to obtain the 1H and 15N assignments [28–30]. Spectra were processed with NMRPipe [31] and analysed using CCPN Analysis version 2.4 [32]. All spectra were recorded on a Bruker Avance III HD 800 MHz spectrometer equipped with a triple-resonance cryoprobe.

SEC-MALS

All experiments were conducted at room temperature on a system comprising a Wyatt miniDAWN TREOS multi-angle light scattering detector and a Wyatt Optilab T-rEX refractive index detector coupled with a Superdex 75 10/300 GL (G.E. Healthcare). CXCL8 was analysed at 4.2 mg/ml (0.5 mM) in 20 mM Na phosphate pH 6.5, 100 mM NaCl.

Determination of CXCL8 reactivity and concentration by ELISA

The Human CXCL8 DuoSet ELISA kit (Bio-Techne, Abingdon, UK) was used to determine both antibody recognition and the accurate concentration of CXCL8 produced in the laboratory. The signal detected from diluted CXCL8 samples was compared to commercially available CXCL8 standards generated by serial dilution from 0.015–2 ng/mL.

Culture and transfection of pre-B cells

The L1.2 pre-B cell line was cultured as previously described in "complete" RPMI consisting of base RPMI 1640 medium with Glutamax-I, supplemented with 25 mM HEPES, 10% fetal calf serum, 1 mM sodium pyruvate, 1 mM 2-mercaptoethanol, 1 x non-essential amino acids and 1 x penicillin/streptomycin [33]. Cells were maintained at a density below 1.5x10^6 cells/mL. Transient transfection of L1.2 cells with either the pCI-CXCR1 or pCDNA3-CXCR2 constructs was carried out as previously described using electroporation [34]. Briefly, 1x10^7 L1.2 cells were incubated with 10μg of plasmid DNA in 800μl of base RPMI media. Electroporation was with carried out in a 0.4cm BTX cuvette (VWR, Lutterworth, UK) at 330V and 975μF. Cells were allowed to recover for twenty minutes prior to seeding at 1x10^6 cells/mL in
complete RPMI supplemented with 10mM sodium butyrate. Cells were used for flow cytometry and chemotaxis assays 24 h following transfection.

**Flow cytometry**

Transfected cells were stained with either a PE-conjugated anti-human CXCR1 mAb (Bio-Techne), or a APC-conjugated anti-human CXCR2 mAb (Biolegend) or relevant conjugated isotype controls as previously described [34]. Cells were analysed on a FACSCalibur (BD Biosciences, Wokingham, UK) part of the Sir Alexander Fleming Building Flow Cytometry Facility at Imperial College London. Exclusion of TOPRO-3 and/or forward/side scatted profiles were used to distinguish live cells from dead cells or cell fragments.

**Chemotaxis assays**

Chemotaxis assays were carried out using a modified Boyden chamber as previously described in detail [34]. Briefly, serial dilutions of recombinant CXCL8 (6–77) were generated using chemotaxis buffer (RPMI + 0.1% BSA) and plated in duplicate in the lower wells of a Chemo TX 101–5 chemotaxis plate (Neuroprobe, MD). The permeable membrane was placed on top and CXCR1 or CXCR2 transfectants were resuspended to a concentration of 1x10^7 cells/mL in chemotaxis buffer of which 20 μl were placed on the membrane above the relevant wells. The plate was placed in a humidified chamber at 37˚C, 5% CO_2. Cells were allowed to migrate for 5 hours after which the numbers of migrating cells were enumerated as previously described using the dye Cell Titer Glo (Promega, Southampton UK) [35]. Data were normalised to the signal generated from 2x10^5 cells (input) and expressed as the percentage of cells migrated.

**Results**

**CXCL8 expression and purification**

Shuffle T7 Express *E. coli* facilitates the formation of disulphide bonds in the cytoplasm, typically yielding more of the desired product than periplasmic expression. This strain was utilised to overexpress the SUMO-CXCL8 fusion protein, producing a significant quantity of soluble protein (S1 Fig). Post sonication and lysate clarification, a single nickel affinity purification step yielded pure SUMO-CXCL8 for tag digestion (Fig 1A). Fractions were pooled following SDS-PAGE analysis and dialysed. ULP1 was dialysed separately into reducing agent free buffer to ensure CXCL8 would not be reduced upon digestion. Although ULP1 is a cysteine protease, efficient cleavage has been observed in the absence of β-mercaptoethanol [36]. However, complete removal of the SUMO-3 tag in the absence of a reducing agent requires a higher ULP1 concentration than under standard buffer conditions. Tag removal was therefore carried out at a ratio of 1:25 (ULP1:SUMO fusion substrate) and incubated at 4˚C overnight. Re-purification of the sample using IMAC facilitated the separation of cleaved, untagged CXCL8 from the other tagged components in a single affinity step (Fig 1B).

**CXCL8 produced in-house is chemotactically active**

Plasmids encoding the human CXCL8 receptors CXCR1 and CXCR2 were introduced into the L1.2 cell line and following overnight treatment with sodium butyrate, cell surface expression of CXCR1 and CXCR2 was confirmed by flow cytometry (Fig 2A and 2C). CXCR1 and CXCR2 transfectants were then used to assess the bioactivity of CXCL8 using modified Boyden chamber chemotaxis assays. The precise concentration of our recombinant CXCL8 (6–77) produced in-house was determined using a CXCL8 ELISA. Serial dilutions of in-house and commercially available CXCL8 (6–77) (Bio-Techne) were used in the chemotaxis assays.
Bell-shaped chemotactic responses from both transfectants, typical of such assays were produced by both in-house and commercially available CXCL8. The efficacy of the responses from both CXCR1 and CXCR2 transfectant were similar, with approximately 20% of the transfected cells migrating at the optimal CXCL8 concentration. CXCL8 was found to induce more potent responses from CXCR1 transfectants than from CXCR2 transfectants, notably at the lowest concentrations of CXCL8 used. In both chemotaxis assays, the data from in-house CXCL8 and commercially available CXCL8 were indistinguishable.

![Fig 1. Purification of CXCL8.](https://doi.org/10.1371/journal.pone.0258270.g001)

(Fig 2B and 2D). Bell-shaped chemotactic responses from both transfectants, typical of such assays were produced by both in-house and commercially available CXCL8. The efficacy of the responses from both CXCR1 and CXCR2 transfectant were similar, with approximately 20% of the transfected cells migrating at the optimal CXCL8 concentration. CXCL8 was found to induce more potent responses from CXCR1 transfectants than from CXCR2 transfectants, notably at the lowest concentrations of CXCL8 used. In both chemotaxis assays, the data from in-house CXCL8 and commercially available CXCL8 were indistinguishable.

![Fig 2. In-house produced CXCL8 is bioactive as deduced by chemotaxis assays.](https://doi.org/10.1371/journal.pone.0258270.g002)

(A and C) Flow cytometry staining showing the cell surface expression of CXCR1 and CXCR2 on transfected L1.2 cells. Data are representative of three independent transfections. (B and D) The relative chemotactic activities of commercially available and in-house generated CXCL8 on CXCR1 and CXCR2 transfectants. Mean percentage migration is shown together with SEM (n = 3).
NMR analysis of CXCL8

NMR spectroscopy is a robust technique for assessing the folded state of proteins and has been used extensively to structurally characterise chemokines. One dimensional $^1$H spectrum was recorded to assess the folded state of CXCL8 produced in this study (S2 Fig). In aqueous buffer the spectrum yields well-dispersed amide and methyl regions indicative of a folded sample, which is consistent with published data of monomeric and dimeric forms [9, 37, 38].

A ($^1$H, $^{15}$N) HSQC spectrum of uniformly [U-$^{15}$N]-labelled CXCL8 recorded at 0.5 mM is well-resolved, exhibits broad chemical shift dispersion typical of a native globular protein and is comparable to published spectra of folded CXCL8 (Fig 3) [9, 37, 38]. The spectrum exhibits 83 peaks in line with the expected number of backbone and side chain resonances for this 72 amino acid protein. X-ray crystallographic and NMR analysis have shown that CXCL8 is a homodimer at $\mu$M concentrations up to 2 mM, so it would be expected that a dimer is observed here [24, 25, 39]. To confirm this dimeric state, Size Exclusion Chromatography in tandem with Multi-Angle Laser Light Scattering (SEC-MALS) was carried out on CXCL8 at 0.5 mM. A single species was observed during the run, indicating sample homogeneity, with a molecular weight of 16.5 kDa $\pm$ 1.7% reported (S3 Fig). This is in line with the expected molecular weight of the dimeric form of CXCL8 produced in this study (16.7 kDa).

A $^1$H and $^{15}$N sequential assignment of CXCL8 was performed using $^{15}$N-HSQC-TOCSY and $^{15}$N-HSQC-NOESY spectra, which was comparable to published data [25, 40]. The assignment covers 99% of the backbone, excluding proline residues and the N-terminal serine residue which could not be assigned. A complete list of the $^1$H and $^{15}$N NMR chemical shifts assigned in this study are detailed in S1 Table.

The dimer interface of CXCL8 (6–77) was shown to be stabilised by hydrogen bonds between Strand 1, an anti-parallel $\beta$-sheet spanning residues 23 to 30, of each subunit [25]. Intermolecular NOEs were observable in our data, confirming this expected connectivity. We observed connectivity between 27HN-25HB2 and 25HB3, 29HN-24HA, 25HN-27HN, 25HN-

Fig 3. $^1$H, $^{15}$N-HSQC spectrum of [U-$^{15}$N]-labelled CXCL8 recorded at 298K. The spectrum is indicative of a folded sample with well dispersed and resolved peaks. 83 peaks are observed consistent with the expected number of backbone and side chain resonances. 67 peaks were assigned to the backbone yielding 99% sequence coverage, excluding the 4 proline residues. The N-terminal serine residue could not be assigned.
27HB and 25HN-28HA, in line with the hydrogen bonding pattern elucidated by Clore et al. (1990).

Discussion

Here we present an efficient protocol for expressing soluble CXCL8 as a SUMO fusion in E. coli Shuffle T7 Express. We detail an effective purification schedule, encompassing nickel affinity purification, ULP1-mediated SUMO tag removal in a non-reducing environment and reverse IMAC purification separating untagged CXCL8 from the other tagged components. CXCL8 produced by this method is pure, correctly folded and bioactive, inducing chemotaxis of CXCR1 and CXCR2 transfectants with identical potency and efficacy to that commercially available CXCL8. Typically, 15 to 20 mg of CXCL8 are produced by this method per litre of cell culture.

The pET-32 Xa/LIC expression system, which requires Factor Xa for tag digestion, has been utilised extensively to produce CXCL8 [9–12]. Both ULP1 and Factor Xa have been employed to generate the correct N-terminus in recombinant protein production, which is a stringent requirement of functional chemokine production. However, Factor Xa mediated digestion often results in cleavage at undesired cryptic sites within the protein of interest, limiting the wider applicability of this system [13]. ULP1 is highly specific as it recognises the SUMO fold, a distinct advantage over Factor Xa, and can accommodate any residue at the N-terminus with the exception of proline [36]. Application of this expression and purification protocol to other chemokines could provide streamlined recombinant production of these proteins.

It should be noted that chemokines can also be produced via chemical synthesis routes, which carry considerable advantages over recombinant production, such as the ease of incorporating chemical modifications and the ability to generate multiple isoforms in one reaction schedule [41]. However, folding of the synthesised chemokine still requires optimisation and there is a requirement for expertise and equipment to run the synthesis cycle.

By producing soluble chemokines that are folded within the host, this methodology may have utility in the production of chemokines that diverge from the classic chemokine fold, such as those with an extra disulphide bond distal to the chemokine core. Structural determination of these recalcitrant proteins has shown them to be highly variable and has utilised refolding, in the case of CCL21 [42, 43], CCL23 [44] and CCL28 [45], or peptide synthesis routes, for CCL1 [46] and CCL15 [47]. However, challenging chemokines with an extra disulphide bond, such as CXCL16 and CXCL17, remain structurally uncharacterised. Refolding and synthetic routes have undoubtedly yielded results, but the method outlined here may simplify protein production at the levels required for structural characterisation while eliminating the requirement for the optimisation of protein refolding.

Supporting information

S1 Raw images. Image 1A is an uncropped gel image corresponding to Fig 1A. Image 1B is an uncropped gel image corresponding to—Fig 1B. Image S1 relates to S1 Fig. All lanes are marked in accordance with labelling in the manuscript and any unused lanes are marked with an X.

(TIF)

S1 Fig. Soluble expression of CXCL8. SDS-PAGE analysis of CXCL8-SUMO3 expression in Shuffle T7 express E. coli cells in 10 ml M9 minimal media per condition. The lanes are labelled (1) uninduced control, (2) 0.1 mM IPTG at 16°C, (3) 0.5 mM IPTG at 16°C, (4) 1 mM IPTG at
16˚C, (5) 0.1 mM IPTG at 30˚C, (6) 0.5 mM IPTG at 30˚C and (7) 1 mM IPTG at 30˚C.

S2 Fig. 1D 1H NMR spectrum of CXCL8. 1D 1H NMR spectra of CXCL8 were recorded at 100 μM. The spectrum exhibits well dispersed chemical shifts, indicative of a well-folded sample.

S3 Fig. SEC-MALS of CXCL8 indicates dimerization. Differential refractive index and molar mass (g/mol) are plotted against elution volume. The differential refractive index is reported in blue. The molecular weight was calculated from the black line, which corresponds to the area of the peak used for this calculation. The reported molecular weight was 16.5 kDa ± 1.7%, in line with the expected molecular weight of the CXCL8 dimer which is 16.7 kDa.

S1 Table. A complete list of the 1H and 15N NMR chemical shifts assigned in this study.

Acknowledgments
We thank Clementina Barone and Arianna Auilito (University of Campania “Luigi Vanvitelli”, Naples, Italy) for assistance with the CXCL8 ELISA.

Author Contributions
Conceptualization: Sophie McKenna, James Edward Pease.
Funding acquisition: Stephen John Matthews, James Edward Pease.
Investigation: Sean Patrick Giblin, Yingqi Xu.
Methodology: Sophie McKenna, Rosemarie Anne Bunn, James Edward Pease.
Writing – original draft: Sophie McKenna.
Writing – review & editing: Sophie McKenna, Sean Patrick Giblin, Rosemarie Anne Bunn, Stephen John Matthews, James Edward Pease.

References
1. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014; 66(1):1–79. https://doi.org/10.1124/pr.113.007724 PMID: 24218476
2. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012; 36(5):705–16. Epub 2012/05/29. https://doi.org/10.1016/j.immuni.2012.05.008 PMID: 22633458
3. Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem. 1994; 269(23):16075–81. PMID: 8206907
4. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, et al. Structure-activity relationships of chemokines. J Leukoc Biol. 1995; 57(5):703–11. https://doi.org/10.1002/jlb.57.5.703 PMID: 7759949
5. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem. 1991; 266(34):32128–34. PMID: 1744111
6. Wang X, Watson C, Sharp JS, Handel TM, Prestegard JH. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. Structure. 2011; 19(8):1138–48. https://doi.org/10.1016/j.str.2011.06.001 PMID: 21827949

7. Elsner J, Petering H, Höchstetter R, Kimmig D, Wells TN, Kapp A, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol. 1997; 27(11):2892–9. https://doi.org/10.1002/ ej.1830271122 PMID: 9394815

8. Proudfoot AE, Buser R, Boriat F, Alouani S, Soler D, Offord RE, et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem. 1999; 274(45):32478–85. https://doi.org/10.1074/jbc.274.45.32478 PMID: 10542293

9. Berkamp S, Park SH, De Angelis AA, Marassi FM, Opella SJ. Structure of monomeric Interleukin-8 and its interactions with the N-terminal Binding Site-I of CXCR1 by solution NMR spectroscopy. Journal of biomolecular NMR. 2017; 69(3):111–21. https://doi.org/10.1007/s10858-017-0128-3 PMID: 29143165

10. Fernando H, Nagle GT, Rajarathnam K. Thermodynamic characterization of interleukin-8 monomer binding to CXCR1 receptor N-terminal domain. FEBS J. 2007; 274(1):241–51. https://doi.org/10.1111/j.1742-4658.2006.05579.x PMID: 17222184

11. Joseph PRB, Sawant KV, Isley A, Pedroza M, Garofalo RP, Richardson RM, et al. Dynamic conformational switching in the chemokine ligand is essential for G-protein-coupled receptor activation. The Biochemical journal. 2013; 456(2):241–51. https://doi.org/10.1042/BJ20130148 PMID: 24032673

12. Rajagopalan L, Rajarathnam K. Ligand Selectivity and Affinity of Chemokine Receptor CXCR1: ROLE OF N-TERMINAL DOMAIN. Journal of Biological Chemistry. 2004; 279(29):30000–8. https://doi.org/10.1074/jbc.M313833200 PMID: 15133028

13. Jenny RJ, Mann KG, Lundblad RL. A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. Protein Expression and Purification. 2003; 31(1):1–11. https://doi.org/10.1016/s1046-5928(03)00168-2 PMID: 12963335

14. Fox JC, Tyler RC, Peterson FC, Dyer DP, Zhang F, Linhardt RJ, et al. Examination of Glycosaminoglycan Binding Sites on the XCL1 Dimer. Biochemistry. 2016; 55(8):1214–25. https://doi.org/10.1021/acs.biochem.5b01329 PMID: 26836755

15. Veldkamp CT, Koplinksi CA, Jensen DR, Petersohn FC, Smits KM, Smith BL, et al. Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol. 2016; 570:539–65. https://doi.org/10.1016/bs.mie.2015.09.031 PMID: 26921961

16. Gregory H, Young J, Schröder J-M, Mrowietz U, Christophers E. Structure determination of a human lymphocyte derived neutrophil activating factor (LYNAP). Biological and Biophysical Research Communications. 1988; 151(2):883–90. https://doi.org/10.1016/s0006-291x(88)80364-4 PMID: 3279957

17. Van Damme J, Van Beeumen J, Opdenakker G, Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J Exp Med. 1988; 167(4):1364–76. https://doi.org/10.1084/jem.167.4.1364 PMID: 3258625

18. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochemical and Biophysical Research Communications. 1987; 149(2):755–61. https://doi.org/10.1016/0006-291x(87)90432-3 PMID: 3322281

19. Yoshimura T, Matsushika K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84(24):9233–7. https://doi.org/10.1073/pnas.84.24.9233 PMID: 3480540

20. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med. 2002; 1(1):19–25. https://doi.org/10.1016/BF03257159 PMID: 14720072

21. Vanheule V, Metzemaekers M, Janssens R, Struyf S, Proost P. How post-translational modifications influence the biological activity of chemokines. Cytokine. 2018; 109:29–51. https://doi.org/10.1016/j.cyto.2018.02.026 PMID: 29903573

22. Proost P, Loos T, Mortier A, Schutyrer E, Gouwy M, Noppen S, et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med. 2008; 205(9):2085–97. https://doi.org/10.1084/jem.20080305 PMID: 18710930

23. Das ST, Rajagopalan L, Guerrero-Plata A, Sai J, Richmond A, Garofalo RP, et al. Monomeric and Dimeric CXCCL8 Are Both Essential for In Vivo Neutrophil Recruitment. PloS one. 2010; 5(7):e11754. https://doi.org/10.1371/journal.pone.0011754 PMID: 20668777

24. Baldwin ET, Weber IT, St Charles R, Xuan JC, Appella E, Yamada M, et al. Crystal structure of interleukin-8: symbiosis of NMR and crystallography. Proceedings of the National Academy of Sciences. 1991; 88(2):502. https://doi.org/10.1073/pnas.88.2.502 PMID: 1989949
25. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM. Three-dimensional structure of interleukin 8 in solution. Biochemistry. 1990; 29(7):1689–96. doi:10.1021/bi00459a004 PMID: 2184886

26. Rajarathnam K, Clark-Lewis I, Sykes BD. 1H NMR Solution Structure of an Active Monomeric Interleukin-8. Biochemistry. 1995; 34(40):12983–90. https://doi.org/10.1021/bi00040a008 PMID: 7548056

27. Matsushima K, Morishita K, Yoshimura T, Lavu S, Kobayashi Y, Lew W, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med. 1988; 167(6):1883–93. https://doi.org/10.1084/jem.167.6.1883 PMID: 3260265

28. Marion D, Driscoll PC, Kay LE, Wingfield PT, Bax A, Gronenborn AM, et al. Overcoming the overlap problem in the assignment of proton NMR spectra of larger proteins by use of three-dimensional heteronuclear proton-nitrogen-15 Hartmann-Hahn-multiple quantum coherence and nuclear Overhauser-multiple quantum coherence spectroscopy: application to interleukin 1.beta. Biochemistry. 1989; 28(15):6150–6. https://doi.org/10.1021/bi00441a004 PMID: 2675964

29. Marion D, Kay LE, Sparks SW, Torchia DA, Bax A. Three-dimensional heteronuclear NMR of nitrogen-15 labeled proteins. Journal of the American Chemical Society. 1989; 111(4):1515–7.

30. Zuiderweg ERP, Fesik SW. Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a. Biochemistry. 1989; 28(6):2387–91. https://doi.org/10.1021/bi00342a006 PMID: 2730871

31. Delaglio F, Grzesiek S, Sau—Vuister GW, Vuister G, Sau—Pfeifer J, Pfeifer J Fau—Bax A, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 2005; 6(3):277–93.

32. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Linus M, et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins. 2005; 59(4):867–96. https://doi.org/10.1002/prot.20449 PMID: 15815974

33. Nedjadi, Li H, Stroke IL, Wise EL, Webb ML, Merritt JR, et al. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br J Pharmacol. 2012; 166(3):912–23. Epub 2011/09/08. https://doi.org/10.1111/j.1476-5381.2011.01660.x PMID: 21895630

34. Viney JM, Andrew DP, Phillips RM, Meisser A, Patel P, Lennartz-Walker M, et al. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. Journal of immunology (Baltimore, Md: 1950). 2014; 192(7):3419–27. https://doi.org/10.4049/jimmunol.1300232 PMID: 24563252

35. Vaidehi N, Pease JE, Horuk R. Chapter 13 Modeling Small Molecule– Protein–Coupled Receptors. Methods in Enzymology. 460: Academic Press; 2009. p. 263–88. https://doi.org/10.1016/S0076-6879(09)05213-6 PMID: 19446730

36. Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR. SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics. 2004; 5(12):2955–705. https://doi.org/10.1016/j.jbf.2017.09.041 PMID: 29262362

37. Park SH, Berkamp S, Radoicic J, De Angelis AA, Opella SJ. Interaction of Monomeric Interleukin-8 with CXCR1 Mapped by Proton-Detected Fast MAS Solid-State NMR. Biophysical Journal. 2011; 113(2):194–203. https://doi.org/10.1016/j.bpj.2011.08.025 PMID: 22019593

38. Rajarathnam K, Kay CM, Clark-Lewis I, Sykes BD. Characterization of quaternary structure of interleukin-8 and functional implications. Methods in Enzymology. 287: Academic Press; 1997. p. 89–105. https://doi.org/10.1016/S0076-6879(97)87007-9 PMID: 9390317

39. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM. Determination of the Secondary Structure of Interleukin-8 by Nuclear Magnetic Resonance Spectroscopy*. Journal of Biological Chemistry. 1989; 264(32):18907–11. PMID: 2681204

40. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM. Determination of the Secondary Structure of Interleukin-8 by Nuclear Magnetic Resonance Spectroscopy*. Journal of Biological Chemistry. 1989; 264(32):18907–11. PMID: 2681204

41. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM. Determination of the Secondary Structure of Interleukin-8 by Nuclear Magnetic Resonance Spectroscopy*. Journal of Biological Chemistry. 1989; 264(32):18907–11. PMID: 2681204

42. Love M, Sandberg JL, Ziarek JJ, Gerarden KP, Rode RR, Jensen DR, et al. Solution Structure of CCL21 and Identification of a Putative CCR7 Binding Site. Biochemistry. 2012; 51(3):733–5. https://doi.org/10.1021/bi201601k PMID: 22221285

43. Smith EW, Lewandowski EM, Moussouras NA, Kroeck KG, Volkman BF, Veldkamp CT, et al. Crystallographic Structure of Truncated CCL21 and the Putative Sulfotyrosine-Binding Site. Biochemistry. 2016; 55(40):5746–53. https://doi.org/10.1021/acs.biochem.6b00304 PMID: 27617343
44. Rajarathnam K, Li Y, Rohrer T, Gentz R. Solution Structure and Dynamics of Myeloid Progenitor Inhibitory Factor-1 (MPIF-1), A Novel Monomeric CC Chemokine*. Journal of Biological Chemistry. 2001; 276(7):4909–16. https://doi.org/10.1074/jbc.M005085200 PMID: 11060285

45. Thomas MA, He J, Peterson FC, Huppler AR, Volkman BF. The Solution Structure of CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity. Journal of molecular biology. 2018; 430 (18, Part B):3266–82.

46. Keizer DW, Crump MP, Lee TW, Slupsky CM, Clark-Lewis I, Sykes BD. Human CC Chemokine I-309, Structural Consequences of the Additional Disulfide Bond. Biochemistry. 2000; 39(20):6053–9. https://doi.org/10.1021/bi000089l PMID: 10821677

47. Sticht H, Escher SE, Schweimer K, Forssmann W-G, Rösch P, Adermann K. Solution Structure of the Human CC Chemokine 2: A Monomeric Representative of the CC Chemokine Subtype. Biochemistry. 1999; 38(19):5995–6002. https://doi.org/10.1021/bi990065i PMID: 10320325